Recombinant Llama Anti-GSN Single Domain Antibody (HPAB-0342CQ) (CAT#: HPAB-0342CQ)

Merikhian, Parnaz, et al. "Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors." Molecular oncology 16.2 (2022): 485-507. https://doi.org/10.1002/1878-0261.13123

This research investigated the anticancer effects of a recombinant nanobody targeting MUC1 tandem repeats. The study demonstrated that this single-domain antibody could effectively inhibit growth, invasion, metastasis, and vascularization in spontaneous mouse mammary tumors. The nanobody showed specificity toward MUC1-overexpressing cancer cells with IC50 values ranging from 1.2 to 14.3 nM, while sparing normal cells. In vivo experiments revealed that the administration of 3 μg nanobody per gram of body weight significantly suppressed tumor growth, reduced pro-inflammatory cytokine levels, and downregulated key biomarkers including Ki-67, MMP9, and VEGFR2. The research highlights the potential of MUC1-targeting nanobodies as therapeutic agents for cancer treatment.
Creative Biolabs provided an irrelevant recombinant Llama anti-GFP nanobody (HPAB-0342CQ), which served as a critical negative control in the immunostaining experiments. This control was essential for validating the specificity of the anti-MUC1 nanobody's cross-reactivity with mouse tumor-associated MUC1, despite significant structural differences between human and mouse MUC1 tandem repeats. This contribution strengthened the study's findings by confirming that the observed therapeutic effects were specifically due to MUC1 targeting rather than non-specific binding.